Trastuzumab deruxtecan
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Brain Cancer
Conditions
Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma
Trial Timeline
Sep 22, 2023 → Sep 22, 2027
NCT ID
NCT06058988About Trastuzumab deruxtecan
Trastuzumab deruxtecan is a phase 2 stage product being developed by AstraZeneca for Brain Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06058988. Target conditions include Brain Cancer, Glioblastoma, Metastatic Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07428044 | Phase 2 | Recruiting |
| NCT07124000 | Pre-clinical | Recruiting |
| NCT06727227 | Pre-clinical | Recruiting |
| NCT06429761 | Approved | Recruiting |
| NCT05965479 | Phase 2 | Recruiting |
| NCT06231693 | Pre-clinical | Terminated |
| NCT05744375 | Phase 2 | Terminated |
| NCT06058988 | Phase 2 | Recruiting |
Competing Products
20 competing products in Brain Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 41 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 52 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 33 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 52 |
| GLIADEL | Eisai | Phase 2 | 52 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 77 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 33 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| ABT-888 | AbbVie | Phase 1 | 33 |
| Veliparib + Placebo | AbbVie | Phase 2 | 52 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 52 |
| Exenatide | AstraZeneca | Approved | 85 |
| AZD5213 | AstraZeneca | Phase 1 | 33 |
| Vorinostat | Merck | Phase 1 | 33 |